PledPharma evaluates commercial potential of myocardial infarction indication
October 14, 2013
PledPharma AB Company Announcement PledPharma evaluates commercial potential of myocardial infarction indication Stockholm, 2013-10-14 08:10 CEST (GLOBE NEWSWIRE) -- The results from the MANAMI study, which was presented this morning, show that PLED substance was well tolerated by patients in the study and can be given to patients suffering from serious heart disease without any side-effects. Despite the study's limited size, a tendency towards clinical effect was seen. In the MANAMI study, patients were pretreated with PLED- substance before PCI (percutaneous coronary intervention) in acute myocardial infarction. The results of the study strengthen the PLED- platform and further reduces the risk. In addition to the results in the MANAMI study, promising results have previously also been shown in the oncology study MANFOL. These studies are based on the same substance platform but in two independent diseases. Rapid restoration of the blood flow (reperfusion) to the heart muscle by PCI is an effective treatment in acute myocardial infarction but reperfusion injury may lead to weakening of the heart’s ability with increased risk of morbidity and mortality. The medical need is thus great since there currently are no drugs that can limit the reperfusion injury. "MANAMI is a small study within a very large and difficult therapeutic area. As PledPharma has previously communicated, we have chosen to focus our resources on the oncology project. However, based on these results we will now evaluate the commercial potential of the myocardial infarction indication”, says CEO Jacques Näsström. For further information please contact: Jacques Näsström, CEO PledPharma, phone +46 73 713 09 79 See also, complementing press release “PledPharma reports results from the MANAMI-study in patients with acute myocardial infarction” About PledPharma PledPharma is a Swedish specialty pharma company that develops PledOx® for prevention of severe chemotherapy-induced side effects in cancer patients. Due to these side effects optimal treatment cannot be carried out. The current market for supportive cancer care is some SEK 72 billion. PledOx protects normal cells against oxidative stress. It belongs to a group of compounds named lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme Manganese SuperOxide Distmutase (MnSOD) – the most important endogenous cellular protectant against devastating oxidative stress. Oxidative stress is a condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of chemotherapy treatment. The company is also evaluating opportunities of using PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
